الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
”Mean Platelet Volume (MPV) could represent an inexpensive marker for use in assessing hepatic inflammation and fibrosis in patients with CLD. So, could MPV have a role in detecting fibrosis regression after SVR in HCV patients treated with DAAs? This study was conducted to: 1. Investigate if there was a significant change in MPV in chronic HCV patients treated with DAAs. 2. Assess if there was a significant correlation between MPV change and changes in clinico-laboratory parameters of fibrosis in HCV patients. Our longitudinal observational study included 500 chronic HCV patients. All patients were eligible for receiving anti-HCV treatment with sofosbuvir plus daclatasvir regimen for 12 weeks, at virology unit, Specialized Medical Hospital, Mansoura University, during period between February 2021 to August 2022. Our study concluded that: • MPV value in chronic HCV patients treated with DAAs was statistically significantly decreased at SVR12. • MPV was positively correlated with advanced APRI score but not with FIB-4 score. • Treatment with DAAs is safe and leads to high rate of viral clearance, a significant rate of improvement in liver function after treatment as it could result in improving of FIB-4 score and APRI. ”